Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
WXSH0208 for Uncomplicated Influenza (Phase II)
CTR20233250Phase 2Completed
- Sponsor
- Chenxin Pharmaceutical
- Start
- Oct 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of WXSH0208 in Influenza A infection and influenza B (3 arms), sponsored by Chenxin Pharmaceutical. Primary endpoint: Time to influenza virus RNA negativity by RT-PCR. Started Oct 2023; status: completed.
02
Drugs
WXSH0208
03
Conditions
Influenza A infectioninfluenza B
Beyond the preview
Go deeper on CTR20233250.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20233250.